Genzyme T. Repair - 500 Beiträge pro Seite

[actnow3]

Ein Top - Biotech TIP :

Gen zieht heute aber sehr gut ab.

Habt Ihr vielleicht neuigkeiten für diese Aktie.

Naja, 30 % ist doch relativ gut oder ?

Warte auf Antwort.

[Narcotics]

Kein Tip.
In US-Kreisen bereits seit über 6Monaten Heiss gehandelt
durchgehen von analysten auf buy-strong buy gesetzt.
Arbeiten an Körpereigenen ersatzstoffen zb. ein kniegelenk aus körpereigenm Material gezüchtet, sowie Hauttransplantate sowie in Zukunft ganze Organe.....
Bin vom Fach und kann nur sagen das die Story und die fundamentals
Stimmen. Breakeaven nächstes bis spatestens 1Q2002 erwartet.
Bin letzten Sommer bei 1,53 rein und gebe sie so schnell nicht her.
Wenn du weitere AUssichtsreiche Titel suchst versuchs mit Enzon.
Nachzulesen unter www.bigcharts.com oder www.siliconinvestor.com
gruß euer Doc.

[actnow3]

Hi- Hallo,

vielen Dank für die Antwort.

Hast du vielleicht ein KZ für die nächsten 6 Monate ?

Oder anders, werden wir die alten Höhen deiner Meinung nach dieses jahr noch sehen.

Bitte um fundierte Informationen.

Danke nochmals.

actnow3 - to keep your money !!!

[lecu68]

Genzyme?

von der Aktie will niemand was wissen. Keine Umsätze!! In Amerika will ebenfalls fast keiner von der Aktie was wissen.

Schau dir mal die Zahlen an. Wenn ich mir die Verbindlichkeiten anschaue, wird mir schlecht.

Ich glaube Du hast die Falsche Aktie gekauft. Denn es gibt viele die mit Genzyme anfangen.

Nix für Ungut
lecu68

[Narcotics]

Iecu 68
vielleicht solltest du dir das Biotech Umfeld un den USA einmal ansehen da sin 80% der Firmen mit einem Breakeaven für nach 2002-2003
DABEI wird mir SCHLECHT.
GZTR hat den großen Vorteil die Genzyme corp. im Rücken zu haben un auf deren Datenbanken zugriff zu besitzen ... ist so ähnlich wie
Telecom und T-online....
Und was den Umsatz betrifft ist es einfach zu erklären.
Geringe Marktkapitalisierung, geringe Umsätze führen v.a. im ABwärtstrend zu Kursschwankungen..., Die Zocker sind mittlerweile aus der Aktie raus ... zum Glück. Denn wer sie besitzt und ich meine so ca. 1 JAhr. was immerhin ca. 60-80% der Aktionäre sind...oder rede ich hier mit gewieften ZOCKERN... oder etwa doch mit Investoren...
Nicht das Ihr mich falsch versteht dies ist kein PUSHVERSUCH...
bin seit 1,5 Euro dabei und auch aus Chartechnischer sicht nach durchbrechen der 30 Tage -linie ist noch einiges zu erwarten.
Und v.a. nochmal für alle zum mitschreiben: Breakeaven für 2001
schau mal unter www.bigcharts.com und unter der Einschätzung
von "Salomon Smith Barney" und die sollten dir als Börsenguru doch was sagen oder ???
also nix für ungut
Ciao.
P.s. schau dir doch auch mal 873997 an.
Grüße euer Doc.

[Narcotics]

Ich vergaß natürlich die Fakten
Sorry hier sind sie da ihr wahrscheinlich kein accout für die AMi-Analysten habt. Sind zwar teuer aber zahlen sich aus.
Gruß euer Doc.


Genzyme Tissue Repair Reports 46 Percent Increase in Revenues - Remains On Track to Reach Break Even Goal
Date: April 19, 2000

Genzyme Tissue Repair (Nasdaq: GZTR) today reported revenues of $5.9 million for the first quarter of 2000, a 46 percent increase from $4.0 million in revenues reported in the first quarter of 1999.
Increases in product revenue were led by a 64 percent growth in U.S. sales of Carticel® (autologous cultured chondrocytes). U.S. sales of Carticel increased to $3.8 million for the first quarter of 2000, compared to $2.3 million in the first quarter of 1999.

Net loss for the first quarter of 2000 decreased 48 percent to $5.0 million, as compared to $9.6 million in the first quarter of 1999. The loss per share for the first quarter of 2000 decreased to $0.17 per share, as compared to $0.44 per share in the first quarter of 1999. This improvement is due in part to the transfer of the NeuroCell™ program—a joint venture between Genzyme and Diacrin Inc. to develop therapies for Parkinson’s and Huntington’s diseases—to Genzyme General.

Gross profit more than doubled for the first quarter of 2000, increasing 177 percent to $2.8 million compared to $1.0 million in the first quarter of 1999. Gross margin was 49 percent for the quarter, up from 26 percent for the same quarter last year. The increase in gross profit is due mainly to an increase in sales volume and continued expense controls. Operating losses for the first quarter of 2000 were $4.8 million, a decrease of 34 percent from $7.3 million in the first quarter of 1999.

Worldwide sales of Carticel increased 54 percent to $4.5 million for the first quarter of 2000, up from $2.9 million in the first quarter of 1999. European Carticel sales increased 15 percent to $0.7 million in the first quarter of 2000, up from $0.6 million in the first quarter of 1999.

Revenue from Epicel™ (cultured epidermal autografts) increased 32 percent to $1.3 million in the first quarter of 2000, compared to $1.0 million for the first quarter of 1999. Epicel revenues fluctuate from quarter to quarter depending on the need for severe burn care.

“Genzyme Tissue Repair had an excellent first quarter and is on track to reach break-even in the next 3-4 quarters,” said Russell Herndon, president, Genzyme Tissue Repair. “The strong improvement in our net loss is evidence of our success in growing Carticel sales while controlling expenses. We are confident in our ability to continue this trend and reach our ultimate goal of profitability.”

Genzyme Tissue Repair ended the quarter with $8.4 million in cash and marketable securities. In the first quarter of 2000, Genzyme Tissue Repair drew $5.0 million from its $20.0 million equity line of credit from Genzyme General (Nasdaq: GENZ). It also has access to funding from Genzyme’s revolving credit facility in addition to the $15.0 million remaining in its equity line.

Carticel Performance Indicators

The leading indicators of the business—the number of patients treated and reimbursement approvals—both increased in the first quarter of 2000.

The number of patients worldwide treated with Carticel increased 29 percent in the first quarter of 2000 to 396, up from 306 patients treated in the first quarter of 1999. The number of patients treated in the United States increased 36 percent to 308 in the first quarter of 2000 as compared to 227 patients treated in the first quarter of 1999. The number of patients treated in Europe increased 11 percent to 88 in the first quarter of 2000, as compared to 79 patients treated in first quarter of 1999. The total number of patients treated since the launch of Carticel in March 1995 is 3,952.

As a result of Genzyme Tissue Repair’s effort to gain positive coverage policies from all major providers, reimbursement approvals for individual patients in the United States continued to rise in the first quarter of 2000. Reimbursement rose to 396 individual patients for the first quarter of 2000, up 42 percent from 278 approvals in the first quarter of 1999.

Orthopedic Product Development Update

As part of its commitment to accelerate the development of a next-generation Carticel product, Carticel II, during the first quarter of 2000, Genzyme Tissue Repair obtained from Sentron Medical, Inc. an exclusive worldwide license and related intellectual property rights that include Autologous Chondrocyte Graft (ACG) technology to grow preformed cartilage tissue on a two-dimensional, or flat, surface.

The potential benefits of Carticel II include the ability to perform the implantation in an arthroscopic procedure and eliminate the need for the periosteum, a shin bone membrane sutured over the defect, which makes an open knee surgery necessary. Also, because this preformed cartilage tissue is mature and surrounded by cartilage matrix, Carticel II could significantly reduce patient rehabilitation time and enable surgeons to treat larger and more degenerative defects.

Genzyme Tissue Repair has conducted in vitro preclinical studies using ACG technology, and has chosen to license the technology based on the promising results of these early-stage studies. Pending successful completion of ongoing studies, Genzyme Tissue Repair expects to file an IND for Carticel II as early as 2001.

Genzyme Tissue Repair also believes that ACG technology will allow for the treatment of cartilage defects in other joints including the shoulder, ankle, hip, and wrist.

Genzyme Tissue Repair remains on track to submit a 510(k) filing for Quick Tack™ periosteal fixation system to the United States Food and Drug Administration in the first half of 2000. Quick Tack, a small device designed to be used in place of sutures during the Carticel implant procedure, is expected to simplify the procedure and decrease the time needed for surgery by as much as half. Quick Tack is also the first step toward an arthroscopic Carticel procedure.

Sixth Cartilage Repair Registry Report

In February 2000, Genzyme Tissue Repair reported summary results of its 6th Cartilage Repair Registry, the first report to include data on patients at the 48-month follow-up visit. In the registry, orthopedic surgeons reported that 85 percent of patients treated with Carticel showed improvement in four key measures four years after therapy. The four key measures include clinician and patient evaluations of overall knee condition, patient reports of symptoms, such as pain and swelling, and knee examination results.

The data were presented by Bert Mandelbaum, M.D. of the Santa Monica Orthopedic and Sports Medicine Group during the annual meeting of the American Academy of Orthopedic Surgeons in Orlando.

Carticel Phase IV Study Update

As part of its post-marketing commitment to the United States Food and Drug Administration, Genzyme Tissue Repair has initiated a non-randomized phase IV study that will evaluate patients who are undergoing Carticel implantation as a result of a failure of a non-Carticel cartilage repair procedure. The patient’s response to Carticel and the non-Carticel procedure will be compared.

The first study site was initiated on March 31st in Richmond, Virginia, under principal investigator Dr. Kenneth Zaslav of the Advanced Orthopedic Center. In early April, the first patient consented to participate in the study at this site and is scheduled to be treated in the near future. A second site under principal investigator Dr. Frank Burke of Blue Grass Orthopaedics in Lexington, Kentucky, was also initiated in April. Genzyme Tissue Repair will evaluate approximately 100 patients in this study.

Industrial Biotechnology Award

On March 27, 2000, Genzyme Tissue Repair received the Industrial Biotechnology Award from the Biotechnology Division of the American Chemical Society. The award recognizes the importance and innovative nature of the Carticel technology, the challenges that were successfully overcome in commercializing the product, and Genzyme Tissue Repair’s contribution in advancing the state-of-the-art in bio-process technology.

The American Chemical Society (ACS) is a not-for-profit membership organization, founded in 1876 and chartered by a 1937 Act of the U.S. Congress. With a membership of nearly 159,000 chemists, chemical engineers, and other practitioners of the chemical sciences, it is the world`s largest scientific society. ACS is recognized as a world leader in fostering scientific education and research, and promoting the public`s understanding of science.

Genzyme Biosurgery Update

On April 18, Genzyme Corp. and Biomatrix filed a joint proxy statement/prospectus for the planned creation of Genzyme Biosurgery, a new Genzyme division with its own newly created stock. The joint proxy statement/ prospectus will be mailed to Genzyme Tissue Repair shareholders in mid-May.

Genzyme Biosurgery will combine the assets of Genzyme Tissue Repair, Genzyme Surgical Products (Nasdaq: GZSP), and Biomatrix (NYSE: BXM). The merger will create the foremost company in biosurgery, the rapidly emerging market in which sophisticated biomaterials and biological products are used to enhance or replace conventional surgical procedures.

The transaction is on schedule to close by the end of June 2000, pending regulatory and shareholder approvals. Genzyme Tissue Repair shareholders will hold approximately 27 percent of the new division and will receive 0.3352 shares of Genzyme Biosurgery stock for each share of GZTR stock.

In addition to filing the joint proxy statement/prospectus, Genzyme and Biomatrix have also filed a notification of the merger with the Department of Justice and the Federal Trade Commission, as required under the Hart-Scott-Rodino Anti-Trust Improvements Act. A special meeting of Genzyme shareholders to vote on proposals related to the creation of Genzyme Biosurgery has been scheduled for June in Cambridge, Mass.

Genzyme Tissue Repair is a leading developer of biological products for the treatment of orthopedic injuries such as cartilage damage, and severe burns. It is a division of Genzyme Corp. and has its own common stock intended to reflect its value and track its performance.

This press release contains forward-looking statements, including statements about Genzyme Tissue Repair’s plans to break-even, Genzyme Tissue Repair’s ability to achieve profitability, the anticipated benefits of Carticel II, potential uses for the ACG technology, the expected benefits of Quick Tack, the anticipated timing of regulatory submissions and completion of preclinical studies, the anticipated design and conduct of post marketing studies, the planned acquisition of Biomatrix, the anticipated creation of Genzyme Biosurgery and a new publicly traded stock, the expected growth and success of Genzyme Biosurgery, Genzyme Biosurgery’s anticipated impact on Genzyme Corp.’s involvement in the biosurgery market, the timing for the creation of Genzyme Biosurgery and the expected allocation of Genzyme Biosurgery stock to Genzyme Tissue Repair stockholders. Actual results could differ materially due to numerous factors, including the results of operations, the actual benefits of Carticel II and the ACG technology, the actual benefits of Quick Tack, enrollment rates for trials, the actual safety and efficacy of products, the timing and content of submissions to and decisions by the FDA and other regulatory authorities, the likelihood of regulatory and other approvals of the planned acquisition of Biomatrix and the creation of Genzyme Biosurgery and related matters, the accuracy of information about the biosurgery market, the competitive environment for the biosurgery market and market acceptance of the Genzyme divisions’ products.





















GENZYME TISSUE REPAIR
Combined Statements of Operations Three Months Ended
(Amounts in thousands, except per share amounts) March 31,
2000 1999

Total revenues $5,867 $4,023
Operating costs and expenses:
Cost of services sold 3,023 2,998
Selling, general and administrative 5,739 6,314
Research and development 1,871 1,968
Total operating costs and expenses 10,633 11,280
Operating loss (4,766) (7,257)

Other income (expenses):
Equity in net loss of joint venture - (2,007)
Other (5) -
Interest income 102 93
Interest expense (302) (445)
Total other income (expenses) (205) (2,359)
Net loss $(4,971) $(9,616)
Net loss per GZTR common share (basic and diluted) $(0.17) $(0.44)
Weighted average shares outstanding 28,531 21,945


Condensed Combined Balance Sheets March 31, December 31,
(In thousands) 2000 1999

Cash and all marketable securities $8,444 $9,373
Other current assets 8,117 7,615
Property, plant and equipment (net) 2,343 2,545
Other assets 104 115
Total assets $19,008 $19,648
Current liabilities $3,235 $4,876
Noncurrent liabilities 18,190 18,227
Division equity (2,417) (3,455)
Total liabilities and division equity $19,008 $19,648



Carticel Performance Indicators
1995 1996 1997 1998 1Q99 2Q99 3Q99 4Q99 1Q00 Since
Inception

Patients
Treated
US 60 251 476 855 227 258 252 339 308 3026
Europe/ROW 0 52 184 239 79 121 70 93 88 926
Total treated 60 303 660 1094 306 379 322 432 396 3952
US Reimbursement
Activity
Third party coverage
(est millions of lives) 101 525 141 142 164 169 179

Cumulative # of Payors
With protocol to
routinely
pay for Carticel 67 325 89 92 99 101 103
US Patient
Approvals 72 301 543 1078 278 335 324 377 396



Please call Genzyme`s corporate communications department at 1-617-252-7570 for additional information.

Subscribe to our press release mailing list.



Sorry ist ein wenig lang
aber dafür fundiert.

[wenzw]

up

[actnow3]

Hallo Leute,

habt ihr irgendwelche news.

Irgendwie ist diese Aktie immer vom gesamten Biotechwerten abhängig.

Außerdem habe ich gar keine Adressen wo ich Informationen über diese Aktie erhalten kann.

Wäre sehr dankbar für news.

Bis dann...

[ShiningAton]

@actnow3

Um infos zu erhalten hilft es zum beispiel auf div. Finanzseiten zu gehen. Hier einige die mir gerade einfallen:

Freerealtime.com
finance.Yahoo.com
quote.com

alles klar?

Ich interessiere mich nur für den wert weil mein Vater einige Besitzt die bisher recht ordentliche Gewinne eingefahren haben.

[actnow3]

@ShiningAnton

Vielen Dank.

Werde gleich mal die Adressen ausprobieren. Mich interessieren vor allem die Informationen warum diese sich nicht richtig bewegen.

Denn wenn die Biotechs fallen, folgt die Aktie. Steigen diese aber, naja dann passiert da halt nicht viel.

Troztdem Dausen dank.

actnow3

[gholzbauer]

Vielleicht kommt etwas mehr Bewegung in den Kurs, wenn die Fusion GZTR-GZSP-BXM durchgeführt ist. Die entstehende Gesellschaft wird eine gute Stellung in ihrem Marktsegment haben und BXM macht schon seit einiger Zeit Gewinne (bilanziell meine ich, weniger der Kurs). Die neue Gesellschaft wird von den Analysten bald stärker beachtet werden, allein schon wegen des größeren Marktwertes.
gholzbauer

[actnow3]

Hallo gholzbauer,

wann ist das denn geplant, diese Fusion.

Vielleicht eine adresse.

vielen dank.

[gholzbauer]

Genzyme Tissue Repair Reports 42 Percent Increase in U.S. Carticel Sales
CAMBRIDGE, Mass., Jul 19, 2000 /PRNewswire via COMTEX/ -- Genzyme Tissue Repair (Nasdaq: GZTR chart, msgs) today reported revenues of $6.3 million for the second quarter of 2000, a 35 percent increase from $4.7 million in revenues reported in the second quarter of 1999.
Increases in revenue were led by a 42 percent growth in U.S. sales of Carticel(R) (autologous cultured chondrocytes). U.S. sales of Carticel increased to $4.0 million for the second quarter of 2000, compared to $2.8 million in the second quarter of 1999.
Net loss for the second quarter of 2000 decreased 52 percent to $4.0 million, as compared to $8.4 million in the second quarter of 1999. The loss per share for the second quarter of 2000 decreased to a loss of $0.14 per share, as compared to a loss of $0.37 per share in the second quarter of 1999. This improvement is due to increased revenue and gross margin improvement, as well as the transfer of the NeuroCell program-a joint venture between Genzyme and Diacrin, Inc.-to Genzyme General (Nasdaq: GENZ chart, msgs) in May 1999.
Gross profit more than doubled for the second time this year, increasing 126 percent in the second quarter of 2000 to $3.3 million compared to $1.4 million in the second quarter of 1999. Gross margin as a percent of total revenue was a record 52 percent for the quarter, up from 31 percent for the same quarter last year. The increase in gross profit is due mainly to an increase in sales volume and leveraging of production production costs. Operating losses for the second quarter of 2000 were $3.8 million, a decrease of 41 percent from $6.7 million in the second quarter of 1999.
"Genzyme Tissue Repair continues to drive Carticel revenues with consistent average yearly growth of 40 percent in U.S. sales," said Russell Herndon, president, Genzyme Tissue Repair. "Additionally, our consistent improvements in gross margin to record levels continue to be a major contributor to our success in decreasing our loss each quarter."
Worldwide sales of Carticel increased 21 percent to $4.6 million for the second quarter of 2000, up from $3.8 million in the second quarter of 1999. European Carticel sales were $0.6 million in the second quarter of 2000, down 42 percent from $1.0 million in the second quarter of 1999, which was an atypical and record quarter for Carticel in Europe.
Revenue from Epicel(TM) (cultured epidermal autografts) increased a record 97 percent to $1.7 million in the second quarter of 2000, compared to $0.9 million for the second quarter of 1999. Epicel revenues fluctuate from quarter to quarter depending on the need for severe burn care.
Genzyme Tissue Repair ended the quarter with $4.4 million in cash. Genzyme Tissue Repair has access to $15.0 million under an interdivisional financing arrangement from Genzyme General, as well as access to additional funding from Genzyme`s revolving credit facility.
Orthopedic Product Development Update
In the second quarter of 2000, Genzyme Tissue Repair submitted a 510(k) filing on schedule to the U.S. Food and Drug Administration (FDA) for clearance to market its Quick Tack(TM) periosteal fixation system. Quick Tack is a small device designed to replace the use of sutures during the Carticel implantation. It is expected to simplify the procedure and decrease the time needed for the surgery. In addition, Quick Tack is the first step from the current open-knee procedure toward an arthroscopic (closed knee) Carticel procedure.
Carticel Phase 4 Study Update
Genzyme Tissue Repair has made significant progress in all of its three Carticel post-marketing studies, including the completion of one study. The studies are required by the U.S. Food and Drug Administration as part of Carticel`s accelerated marketing approval.
During the quarter, the first of these three studies, the Registry Based Study, was completed ahead of schedule and has been sent to the FDA for review. The study met its primary and secondary endpoints related to efficacy. The second post-approval study, called STAR (Study of the Treatment of Articular Repair), is ahead of schedule in site initiation and patient enrollment. Genzyme Tissue Repair received protocol approval for STAR in the first quarter of 2000 and to date, 17 sites have been initiated and 7 patients have received Carticel implantation. Investigators will evaluate approximately 100 patients in this study and will follow these patients for four years.
Genzyme Tissue Repair has also made significant progress in its third post-approval commitment-a preclinical study assessing the contribution of the cells to the cartilage repair. The study is designed to compare the results from the Carticel procedure (cultured cartilage cells implanted in the defect are covered with a patch of periosteum to hold them in place) versus placing periosteum over the defect without Carticel. The periosteum is a membrane covering the shin bone. Data collection for this study is expected to be complete by the end of 2000.
NeuroCell Update
In the second quarter of 2000, the Genzyme Corporation Board of Directors extended the first milestone date for the NeuroCell program. The milestone date to initiate a phase 3 clinical trial of NeuroCell-PD to treat Parkinson`s disease was extended to December 31, 2000, from June 30, 2000.
The milestone date and related financial obligation to Genzyme General were extended to allow time to complete and review the current blinded phase 2 clinical trial. In the meantime, preparations for the phase 3 clinical trial are moving forward. The FDA has reviewed the phase 3 trial protocol and trial sites and investigators have been selected. The first Institutional Review Board (IRB) approval for the protocol was obtained in May 2000.
Genzyme transferred its interest in the NeuroCell joint venture from Genzyme Tissue Repair to Genzyme General in May 1999. The milestone, based on the initiation of a phase 3 clinical trial, is part of the terms of the transfer agreement.
Formation of Genzyme Biosurgery
Progress continues toward the proposed merger which would combine Genzyme Tissue Repair with Genzyme Surgical Products (Nasdaq: GZSP chart, msgs), and acquire Biomatrix Inc. (NYSE: BXM chart, msgs) to form a new publicly-traded division of Genzyme Corporation called Genzyme Biosurgery.
The merger has received clearance from the Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act and is being reviewed by the Securities and Exchange Commission. Once effective, a joint proxy statement/prospectus will be mailed to shareholders of each company. A special shareholder meeting will be held to vote on the proposed merger plan. The meeting is expected to occur in the third quarter.
The formation of Genzyme Biosurgery will create critical mass in the area of bio-orthopedics and establish the business as a leader in this field with two marketed break-through bio-orthopedic products: Biomatrix` Synvisc for osteoarthritis and Carticel. The financial and technical strength of the new business will also allow Genzyme Tissue Repair to accelerate development of its pipeline products including Carticel II, intended to allow implantation arthroscopically, and its small molecule therapy under development for the treatment of osteoarthritis.
Upon formation, Genzyme Biosurgery will have approximately 1,300 employees; six dedicated manufacturing facilities; global clinical and regulatory capabilities; cutting-edge scientific and technological expertise; an extensive intellectual property portfolio; several established sales organizations in focused surgical markets in both the United States and Europe; and marketing and distribution agreements with a number of large, multinational health care companies.
Genzyme Tissue Repair is a leading developer of biological products for the treatment of orthopedic injuries such as cartilage damage, and severe burns. It is a division of Genzyme Corp. and has its own common stock intended to reflect its value and track its performance.
This press release contains forward-looking statements, including statements about Genzyme Tissue Repair`s expected benefits of Quick Tack, the anticipated timing of regulatory submissions and the completion of clinical studies, the planned acquisition of Biomatrix, the anticipated creation of Genzyme Biosurgery, the timing for the creation of Genzyme Biosurgery, the expected growth and success of Genzyme Biosurgery, Genzyme Biosurgery`s anticipated impact on Genzyme Corp.`s involvement in the biosurgery and bio- orthopedic markets and the expected effects of the creation of Genzyme Biosurgery on Genzyme Tissue Repair`s development of products. Actual results may differ materially due to many factors, including the results of operations, the actual benefits of Quick Tack, enrollment rates for trials, the actual safety and efficacy of products, the time involved in compiling and analyzing clinical trial data, the timing and content of submissions to and decisions by the FDA and other regulatory authorities, the likelihood of regulatory and other approvals of the planned acquisition of Biomatrix and the creation of Genzyme Biosurgery and related matters, the operational integration associated with the anticipated transactions and other risks generally associated with such transactions, the accuracy of information about the biosurgery and bio-orthopedic markets, the competitive environment for the biosurgery and bio-orthopedic markets, and the ability to successfully complete preclinical and clinical development of products. GZTR stock is a class of common stock of Genzyme Corporation, therefore GZTR shareholders are subject to the risks and uncertainties described in Genzyme`s filings with the Securities and Exchange Commission under the Exchange Act of 1934, as amended, including Exhibit 99.2 to Genzyme`s Annual Report on Form 10-K for the year ended December 31, 1999.
Genzyme Tissue Repair`s second quarter earnings conference call will be broadcast live over the Internet at 11:00 a.m. EDT today on Genzyme`s website: http://www.genzyme.com/ir/events.htm." target="_blank" rel="nofollow ugc noopener">http://www.genzyme.com/ir/events.htm. The conference call will be available through midnight EDT July 27.
Investors can also listen to a playback of a conference call discussing the second quarter financial results by phone by dialing 1-800-633-8284 in the United States or 1-858-812-6440 elsewhere from 1pm EDT today through 12 midnight EDT July 27. Refer to reservation number 15487322.
Genzyme`s releases are on the World Wide Web at http://www.genzyme.com. They are also available from Genzyme`s fax-on-demand service at 1-800-436-1443 within the United States and 1-201-521-1080 outside the United States.

_ Media Contact: Investor Contact:
_ Elizabeth Heller Kristen Nally
_ 617-761-8419 617-252-7815
_
_
_ GENZYME TISSUE REPAIR
_
_ Combined Statements of Operations
_ (Amounts inarty
_ Coverage (est
_ millions
_ of lives) 164 169 179 179
_
_ Cumulative #
_ of Payors
_ with protocol
_ to routinely pay
_ for Carticel 99 101 103 103
_
_ US Patient
_ Approvals
_ 324 377 396 402
Source: Genzyme Tissue Repair _

[gholzbauer]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[gholzbauer]

Biomatrix Posts Record Product Sales and Revenues - Company Earns $7 Million Milestone From Wyeth-Ayerst -
RIDGEFIELD, N.J., Jul 25, 2000 /PRNewswire via COMTEX/ -- Biomatrix, Inc. (NYSE: BXM chart, msgs) today reported record financial results for the three and six months ended June 30, 2000. During the second quarter of 2000, the company reported net income of $7.7 million or $0.31 per diluted share on revenues of $27.2 million. During the comparable quarter of 1999, the company reported net income of $7.7 million or $0.31 per diluted share on revenues of $25.2 million. During the second quarter 2000, the company`s SG&A expenses included approximately $0.8 million, or $0.02 per diluted share, in costs related to the proposed merger with the Genzyme Corp. Biomatrix ended the second quarter of 2000 with $37.4 million in cash and $85.8 million in shareholders` equity.
U.S. Marketing Partner Posts Strong Synvisc Sales
During the second quarter ended June 30, 2000, Biomatrix earned a $7.0 million milestone payment from Wyeth-Ayerst Laboratories (a division of American Home Products (NYSE:AHP)), marking Wyeth-Ayerst`s attaining $150 million in U.S. Synvisc(R) net sales on a trailing twelve months basis. In the second quarter of 1999, Biomatrix also earned a $7.0 million milestone payment from Wyeth-Ayerst Laboratories, marking Wyeth-Ayerst`s attaining $100 million in U.S. Synvisc(R) net sales on a trailing twelve months basis. "The success of the first quarter 2000 direct-to-consumer advertising campaign, which included the initiation of television advertising, helped drive Synvisc sales throughout the second quarter and demonstrated that viscosupplementation with Synvisc continues to show increasing acceptance among patients and by the U.S. medical community as an important treatment in relieving the pain associated with osteoarthritis of the knee," stated Dr. Endre A. Balazs, M.D., chief executive officer and chief scientific officer of Biomatrix.
Dr. Balazs continued, "During the second quarter of 2000, U.S. Synvisc net sales by Wyeth-Ayerst were $49.1 million, an increase of more than 100% compared to their U.S. Synvisc net sales of $24.3 million recorded during the second quarter of 1999. For the first six months of 2000, Wyeth-Ayerst generated U.S. Synvisc net sales of $80.6 million, a more than 70% increase compared to the $47.0 million in U.S. Synvisc net sales they recorded during the first six months of 1999."
For the first six months of 2000, Biomatrix generated product sales of $36.5 million compared to product sales of $34.6 million recorded during the first six months of 1999. During the second quarter of 2000, Biomatrix posted record product sales of $20.0 million, an increase from $18.1 million in product sales posted during second quarter of 1999. During the first and second quarters of 1999, Synvisc sales to U.S. marketing partner, Wyeth-Ayerst, included an inventory build sufficient to support the Direct-To-Consumer (DTC) Campaign for Synvisc initiated during the second half of 1999.
For the six months ended June 30, 2000, Biomatrix reported net income of $8.2 million, or $0.34 per diluted share, on revenues of $43.9 million. This compares with net income of $11.0 million, or $0.45 per diluted share, on revenues of $41.8 million posted in the first six months of 1999.
Dr. Balazs commented further on the company`s achievements, "Second quarter 2000 was a record quarter for Biomatrix, not only in product sales, but also during the quarter:

_ * we recorded the sale of our 3 millionth Synvisc syringe, which
_ represents 1 million Synvisc treatments since initial launch;
_
_ * Synvisc became one of the top five pharmaceuticals in the
_ anti-arthritic category as ranked in May by IMS Data, making Synvisc
_ the first biomaterial to make the top ten list in this category;
_
_ * U.S. Synvisc net sales by Wyeth-Ayerst in the second quarter of 2000
_ grew over 50% sequentially from U.S. Synvisc net sales of
_ $31.5 million in the first quarter of 2000:
_
_ * we released positive clinical data on the use of Synvisc to treat
_ osteoarthritis of the hip at this year`s Annual European Congress of
_ Rheumatology (EULAR) meeting;
_
_ * we started clinical studies in Europe for Hylagel(R)-Nuro, the
_ company`s injectable gel treatment for the prevention of surgical
_ adhesions following lumbar surgery;
_
_ * we filed a joint proxy with the Securities and Exchange Commission
_ (SEC) which outlines in detail the specifics of the proposed merger
_ with the Genzyme Corp. and which is currently under SEC review."
Dr. Balazs concluded, "Our clinical development program continues to progress, and we look forward to joining forces with the Genzyme companies to accelerate these programs and to establish the new company, Genzyme Biosurgery, as a leader in the hyaluronan-based viscoelastic biomaterials field."
The Creation of Genzyme Biosurgery
Progress continues toward the proposed merger which would combine Genzyme Tissue Repair (Nasdaq: GZTR chart, msgs) with Genzyme Surgical Products (Nasdaq: GZSP chart, msgs) and Biomatrix, Inc. to form a new publicly-traded division of Genzyme Corporation called Genzyme Biosurgery.
The merger has received clearance from the Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act and is being reviewed by the Securities and Exchange Commission. Once effective, a joint proxy statement/prospectus will be mailed to shareholders of each company. A special shareholder meeting will be held to vote on the proposed merger. The meeting is expected to occur in the third quarter.
Upon formation, Genzyme Biosurgery will have a portfolio of innovative, market-leading products; a broad product-development pipeline; a premier manufacturing, marketing, regulatory, and scientific infrastructure; and substantial financial resources.
Genzyme Biosurgery will be composed of Biomatrix, a worldwide leader in the development and manufacture of viscoelastic biomaterials for use in orthopedic and other medical applications; Genzyme Tissue Repair, a leading developer of biological products for the treatment of orthopedic injuries and severe burns; and Genzyme Surgical Products, which develops and markets mechanical devices, biomaterials, and biotherapeutics for cardiothoracic and other surgical markets, and is a leader in developing biomaterials to prevent post-surgical adhesions. As a division of Genzyme Corp., Genzyme Biosurgery will have its own common stock intended to reflect its value and track its economic performance.
Biomatrix, Inc., headquartered in Ridgefield, New Jersey, is an international biomedical company that develops, manufactures and commercializes elastoviscous products made from proprietary biological polymers called hylans which are used in therapeutic medical applications and in skin care products.
Certain statements in this press release are forward-looking statements that involve risks and uncertainties including, but not limited to, the outcome of a class action lawsuit against the company, the regulatory approval process, obtaining and enforcing patents, reimbursement by private health care providers, manufacturing capabilities, projected earnings and financial results, growing product demand, product liability, inventory levels of our marketing partners, future product development, the mailing of a joint proxy statement/prospectus and the holding of a special stockholders meeting in connection with the formation of Genzyme Biosurgery, the completion of the formation of Genzyme Biosurgery, the creation of a new publicly traded stock for Genzyme Biosurgery, the future growth and success of Genzyme Biosurgery, conditions in the financial markets relevant to the proposed creation of Genzyme Biosurgery, the likelihood of regulatory and other approvals of the transaction, the operational integration associated with the formation of Genzyme Biosurgery and other risks generally associated with a transaction of this type, and other risks detailed in Biomatrix` reports filed under the Securities Exchange Act, including Forms 10-Q and Biomatrix` annual report on Form 10-K for the year ended December 31, 1999. For more information on Biomatrix, please visit the Company`s web site at http://www.biomatrix.com.
Biomatrix` earnings conference call will be broadcast live at 8:30 a.m. EDT today on Biomatrix` Web site, http://www.biomatrix.com, on the home page. To listen to the call, you need Real Player and a computer equipped with speakers and a sound card. You can download RealPlayer at the conference call site. A replay of the call will be available until the next company conference call.
Investors are urged to read the joint proxy statement/prospectus relating to the formation of Genzyme Biosurgery filed with the Securities and Exchange Commission because it contains important information. The joint proxy statement/prospectus and other documents filed by Biomatrix and Genzyme with the commission may be obtained free of charge at the commission`s web site (http://www.sec.gov) and from Biomatrix or Genzyme. Requests to Biomatrix may be directed to Anne Marie Fields, or you can access documents on the company`s web site (http://www.biomatrix.com). Requests to Genzyme may be directed to Sally Curley, or you can access documents on the company`s web site (http://www.genzyme.com).
Synvisc(R), and Hylagel-Nuro(R) are registered trademarks of Biomatrix, Inc.

_ BIOMATRIX, INC. AND SUBSIDIARIES
_
_ CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
_ (Unaudited)
_ (in millions, except share and per share data)
_
_ Three Months Ended Six Months Ended
_ June 30, June 30,
_ 2000 1999 2000 1999
_
_ Revenues:
_ Net product sales $20.0 $18.1 $36.5 $34.6
_ Income from licenses,
_ royalties and
_ research contracts 7.2 7.1 7.4 7.2
_
_ Total revenues 27.2 25.2 43.9 41.8
_
_ Costs and expenses:
_ Cost of goods sold 6.0 5.2 11.0 10.1
_ Research and
_ development expenses 2.7 2.0 5.3 4.2
_ Selling, general
_ and administrative
_ expenses 6.2 4.6 14.7 8.5
_
_ Total costs and
_ expenses 14.9 11.8 31.0 22.8
_
_ Income from operations 12.3 13.4 12.9 19.0
_
_ Interest expense (0.3) (0.5) (0.5) (0.9)
_ Interest and
_ miscellaneous income 0.8 0.3 1.3 0.6
_
_ Income before taxes 12.8 13.2 13.7 18.7
_
_ Provision for income
_ taxes 5.1 5.5 5.5 7.7
_
_ Net income $7.7 $7.7 $8.2 $11.0
_
_
_ Net income per share:
_ Basic $0.33 $0.34 $0.35 $0.48
_ Weighted average
_ shares
_ outstanding 23,388,175 22,931,602 23,340,298 22,862,843
_
_ Diluted $0.31 $0.31 $0.34 $0.45
_ Weighted average
_ shares
_ outstanding 24,933,030 25,315,224 24,489,291 25,240,877
Source: Biomatrix, Inc. _

[gholzbauer]

Genzyme Surgical Products Reports Second-Quarter Financial Results
CAMBRIDGE, Mass., Jul 20, 2000 /PRNewswire via COMTEX/ -- Genzyme Surgical Products (Nasdaq: GZSP chart, msgs) announced today that revenues for the second quarter of 2000 were $30.0 million, compared with revenues of $26.7 million for the same quarter in 1999, an increase of 12 percent.
Revenue increases were driven by strong sales across all product lines, particularly instrumentation for beating-heart cardiac surgery and the Sepra(R) line of products. Revenues were affected by the impact of the strong dollar overseas.
The gross margin was 45 percent, up 10 percentage points from the second quarter in 1999, reflecting increased sales volumes, greater sales of higher margin products, and continued improvements in operational efficiencies.
Net loss was $10.4 million, or $.70 per share, down from a net loss of $17.7 million, or $1.19 per share, for the second quarter of 1999.
"We had a solid quarter, with revenue growth across the board, strong sales growth in key product areas, and healthy improvements in our gross margin," said Duke Collier, president of Genzyme Surgical Products. "We have the business moving in a very positive direction, one year after our launch as a separate Genzyme division. The next six months will be an important period for us, as we expect to introduce a number of new products, initiate several gene therapy clinical trials, and-most importantly-create Genzyme Biosurgery, which will be one of the largest and most dynamic businesses bringing biotechnology to surgery."
At the close of the second quarter, Genzyme Surgical Products had approximately $96 million in cash and marketable securities.
Cardiothoracic Surgery
In the second quarter of 2000, revenues from products for cardiothoracic surgery were $19.8 million, up 10 percent compared to revenues of $18.0 million in the second quarter of 1999.
Within the cardiothoracic line, overall sales of minimally invasive devices grew 189 percent this quarter compared to the second quarter of last year, highlighting the rapid market penetration of Genzyme`s instrumentation for beating-heart cardiac surgery and minimally invasive vein harvesting.
Genzyme Surgical Products continues to pursue enhancements to these product lines. During the third quarter, it plans to launch the Immobilizer(TM) system, its third-generation platform for beating-heart surgery. The Immobilizer, which is designed to be easier to use and set up more quickly than Genzyme`s second-generation OPCAB platform, offers surgeons superior stability and a clear operating field, facilitating accurate suturing of delicate coronary vessels. Genzyme also expects to launch its latest generation SaphLITE(TM) system for minimally invasive vein harvesting. The new system is designed to be easier to use than previous generations of the product, preserve vein quality, and provide direct visualization for hands- free retraction.
For lung surgery, Genzyme Surgical Products and Focal Inc. are now launching FocalSeal(R)-L surgical sealant, which received FDA approval during the second quarter. The product is intended for use in sealing air leaks that occur as a result of lung surgery procedures. Genzyme Surgical Products holds exclusive North American marketing and distribution rights for FocalSeal products for a variety of surgical applications.
General Surgery
Revenues from products for general surgery increased 18 percent for the second quarter to $7.4 million, compared with $6.2 million for the same quarter in 1999. Sepra product sales increased 22 percent in the second quarter to $4.3 million, compared with $3.5 million in the same period of 1999.
In June, Genzyme Surgical Products launched Sepramesh(TM) Biosurgical Composite, a prosthetic surgical mesh designed to be sutured in place along the abdominal wall to support and strengthen hernia repairs. The product offers significant advantages over traditional mesh products because it contains a bioresorbable barrier that separates the mesh from underlying organ and tissue surfaces to reduce tissue attachment to the mesh. Sepramesh was also recently approved for use in Europe and Canada.
Other Revenues
Revenues for the second quarter of 2000 also include $2.8 million from sales of instruments for plastic surgery and products sold to original equipment manufacturers, primarily sutures. These products generated $2.4 million in sales in the second quarter of 1999.
Pipeline Update
Genzyme Surgical Products continues to enroll patients in a blinded Phase 1 clinical trial of HIF-1alpha, its proprietary gene therapy product designed to promote the growth of new blood vessels around blocked arteries. The product is being evaluated as a treatment for patients with peripheral vascular disease.
Genzyme Surgical Products is also making good progress toward initiating a second Phase 1 clinical trial of HIF-1alpha to evaluate its use as a treatment for patients with coronary artery disease undergoing bypass surgery who have an area of the heart that is not suitable for surgical revascularization. The IND for this trial has been cleared by the FDA, and patient enrollment is expected to begin following a review of the trial`s protocol by the Recombinant DNA Advisory Committee of the National Institutes of Health. This review is expected to occur during the second half of this year. Additional clinical trials of HIF-1alpha are expected to begin outside the United States within the next few quarters.
Genzyme Biosurgery Update
Progress continues toward the planned formation of Genzyme Biosurgery, a new Genzyme Corp. division with its own newly created stock. Genzyme Biosurgery will be formed by combining Genzyme Surgical Products and Genzyme Tissue Repair (Nasdaq: GZTR chart, msgs) and acquiring Biomatrix Inc. (NYSE: BXM chart, msgs) -- a pioneering and profitable developer of sophisticated biomaterials-to create one of the leading businesses in the market for biotechnology products that improve or replace conventional surgical procedures.
Upon formation, Genzyme Biosurgery will have a portfolio of innovative, market-leading products; a broad product-development pipeline; a premier manufacturing, marketing, regulatory, and scientific infrastructure; and substantial financial resources.
The transaction has received clearance from the Federal Trade Commission, and the joint proxy statement/prospectus is being reviewed by the Securities and Exchange Commission. Once effective, proxy materials will be mailed to shareholders and Genzyme and Biomatrix will each hold a special shareholder meeting to obtain required approvals. The meetings are expected to occur during the third quarter. Genzyme Surgical Products shareholders will be asked to vote to approve several proposals related to the formation of Genzyme Biosurgery.
"We strongly believe that Genzyme Biosurgery-combining important products and innovative product development capabilities from biotechnology with a strong sales force presence in the operating room-will be a formidable entity," said Duke Collier. "For Genzyme Surgical Products shareholders, this transaction will dramatically enhance and expand the biosurgery strategy we defined as our mission one year ago and accelerate its implementation. As we move forward with this process, we continue to reconfirm and broaden our vision of the possibilities and promise offered by this combination of products, technologies, and expertise. We strongly believe that we are in the right place at the right time with the right resources to define and lead a rapidly emerging market. We are firmly committed to completing this transaction, and are working hard to make it happen."
Genzyme Surgical Products develops and markets a portfolio of instruments, devices, biomaterials, and biotherapeutics primarily for the cardiovascular and general surgery markets. It is pioneering the field of biosurgery, which is being created by the increasing convergence of mechanical and biological approaches to surgery and other interventional procedures. A division of the biotechnology company Genzyme Corporation, Genzyme Surgical Products has its own common stock intended to reflect its value and track its economic performance.
This press release contains forward-looking statements, including statements concerning the introduction and success of new products (including the launch of the Immobilizer(TM) system for beating-heart surgery, the SaphLITE(TM) system for minimally invasive vein harvesting and FocalSeal(R)-L surgical sealant for lung surgery), the initiation of gene therapy clinical trials (including a clinical trial for HIF-1alpha), the mailing of a joint proxy statement/ prospectus and the holding of a special stockholders meeting in connection with the formation of Genzyme Biosurgery, the completion of the formation of Genzyme Biosurgery, the creation of a new publicly traded stock for Genzyme Biosurgery, the future growth and success of Genzyme Biosurgery, Genzyme Biosurgery`s impact on Genzyme Corp.`s involvement in the bio- orthopedic and cardiothoracic markets, expected revenues based on new products and the sufficiency of the cash and other resources of Genzyme Biosurgery. Actual results may differ materially depending on many factors including the accuracy of information about the biosurgery market, the competitive environment for the biosurgery market, market acceptance of Genzyme Surgical Product`s products and services, the competitive environment for Genzyme Surgical Product`s products, actual results of operations, the enrollment rate for clinical trials, the ability to successfully complete preclinical and clinical development of products, the actual safety and efficacy of products, the timing and content of submissions to and decisions by the FDA and other regulatory authorities, conditions in the financial markets relevant to the proposed creation of Genzyme Biosurgery, the likelihood of regulatory and other approvals of the transaction, the operational integration associated with the formation of Genzyme Biosurgery and other risks generally associated with a transaction of this type. GZSP stock is a class of common stock of Genzyme Corporation, therefore, GZSP shareholders are subject to the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation Exhibit 99.2 to Genzyme`s 1999 Annual Report on Form 10-K, as amended.
Genzyme Surgical Products` earnings conference call will be broadcast live at 4:45 p.m. EDT today on Genzyme`s Web site at http://www.genzyme.com/ir/events.htm. A replay of the call will be available until midnight July 27.
Investors may also listen to a replay of the conference call by dialing 1- 800-633-8284 in the United States and 1-858-812-6440 outside the United States from 7:00 p.m. EDT today through midnight EDT on July 27. Please refer to reservation number 15488546.
Investors are urged to read the joint proxy statement/prospectus relating to the formation of Genzyme Biosurgery filed with the Securities and Exchange Commission because it contains important information. The joint proxy statement/prospectus and other documents filed by Genzyme and Biomatrix with the commission may be obtained free of charge at the commission`s Web site (www.sec.gov) and from Genzyme or Biomatrix. Requests to Genzyme may be directed to Sally Curley, or you can access documents on the company`s Web site. Requests to Biomatrix should be directed to Anne Marie Fields, or you can access documents on the company`s Web site.

_ Media Contact: Investor Contact:
_ Bo Piela Kim Witkop
_ 617-252-7785 617-761-8563
_
_
_ GENZYME SURGICAL PRODUCTS
_ Combined Statements of Operations
_ (Amounts in thousands, except per share amounts)
_
_ Three Months Ended Six Months Ended
_ June 30, June 30,
_ 2000 1999 2000 1999
_
_ Total revenues $29,969 $26,681 $59,051 $54,034
_
_ Operating costs and expenses:
_
_ Cost of products sold 16,592 17,439 32,631 33,283
_ Selling, general
_ and administrative 17,042 16,492 33,442 31,779
_ Research and
_ development 7,001 8,983 13,972 14,585
_ Amortization of
_ intangibles 1,427 1,444 2,853 2,861
_ Total operating costs
_ and expenses 42,062 44,358 82,898 82,508
_
_ Operating loss (12,093) (17,677) (23,847) (28,474)
_
_ Other income (expenses):
_ Interest income 1,708 56 3,390 63
_ Other 20 (3) 48 43
_ Interest expense (2) (34) (1) (35)
_ Total other income
_ (expenses) 1,726 19 3,437 71
_
_ Net loss $(10,367) $(17,658) $(20,410) $(28,403)
_
_ Per GZSP common share
_ (basic and diluted) $(0.70) $(1.37)
_ Weighted average
_ shares outstanding 14,905 14,880
_
_
_ Condensed Combined Balance Sheets
_
_ June 30, December 31,
_ (In thousands) 2000 1999
_
_
_ Cash and all marketable securities $95,890 $126,125
_ Other current assets 61,223 51,192
_ Property, plant and equipment, net 17,795 17,621
_ Intangibles, net 169,900 172,833
_ Other assets 8,052 3,153
_ Total assets $352,860 $370,924
_
_ Current liabilities $22,478 $17,006
_ Noncurrent liabilities - -
_ Division equity 330,382 353,918
_ Total liabilities and division equity $352,860 $370,924
Source: Genzyme Surgical Products _

[gholzbauer]

Und hier ein Grund, warum der Kurs von Biomatrix etwas gedrückt ist:

Milberg Weiss Announces Class Action Suit Against Biomatrix, Inc.
NEW YORK, Jul 21, 2000 (BUSINESS WIRE) -- The following is an announcement made by the law firm of Milberg Weiss Bershad Hynes & Lerach LLP:
The law firm of Milberg Weiss Bershad Hynes & Lerach LLP announces that a class action lawsuit was filed on July 21, 2000, on behalf of purchasers of the securities of Biomatrix, Inc. ("Biomatrix" or the "Company") (NYSE: BXM chart, msgs) between July 20, 1999 and April 25, 2000, inclusive. A copy of the complaint filed in this action is available from the Court, or can be viewed on Milberg Weiss` website at: http://www.milberg.com/biomatrix/" target="_blank" rel="nofollow ugc noopener">http://www.milberg.com/biomatrix/
The case is pending in the United States District Court for the District of New Jersey, and has not yet been assigned to a judge. The address of the Courthouse is Martin Luther King, Jr. Federal Building and U.S. Courthouse, 50 Walnut Street, Newark, New Jersey 07101.
The Action seeks damages for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The defendants are: Biomatrix, Inc., Endres A. Balazs, Biomatrix`s Chief Executive Officer, Chief Scientific Officer and Director; and Rory B. Riggs, Biomatrix`s President and Director.
Plaintiffs allege that defendants knowingly or recklessly disseminated materially false and misleading statements and omissions that misrepresented the efficacy of its leading product, Synvisc, a gel-like substance used in the treatment of osteoarthritis. Plaintiffs allege that Biomatrix distributes Synvisc primarily through its trading partner, Wyeth-Ayerst Laboratories, a division of Home Products ("Wyeth"). Plaintiffs allege that defendants exaggerated medical community acceptance of Synvisc in the treatment of osteoarthritis and that defendants artificially inflated reported sales of Synvisc by stuffing the distribution pipeline with inventory. Plaintiffs allege that misrepresentations and omissions by defendants influenced the views of stock market analysts and fostered an unrealistically positive assessment of Biomatrix and its business, prospects and operations. Plaintiffs allege that, as a result of such misinformation, Biomatrix`s stock traded at artificially inflated prices throughout the proposed Class Period.
Plaintiffs allege that the following statements, among others, were materially false and misleading:

_ -- 1. During a conference call on July 20, 1999, Riggs told
_ analysts that while Biomatrix`s strategy had been to build
_ inventory, the Company was not going to continue building
_ inventory but rather "manage an even production schedule."
_
_ -- 2. In a Biomatrix press release, dated July 21, 1999, and
_ issued in conjunction with Biomatrix`s second-quarter earnings
_ announcement, Balazs stated that demand for Synvisc was
_ increasing in the United States and Europe and that this
_ increase in demand was evidence of the medical community`s
_ growing acceptance of the use of Synvisc in the treatment for
_ osteoarthritis.
_
_ -- 3. On October 19, 1999, defendants issued a press release over
_ PR Newswire announcing the Company`s third-quarter results
_ without disclosing the effect the Synvisc inventory buildup
_ was having and would have on product sales, revenues and
_ earnings. The Company announced total third-quarter revenue of
_ $18.3 million, and product sales of $18.1 million, compared to
_ third-quarter revenue of $11.6 million and product sales of
_ $11.5 million recorded during the third quarter of 1998.
_
_ -- 4. On November 15, 1999, Biomatrix filed its Form 10-Q for the
_ third-quarter of 1999, the period ending September 30, 1999,
_ in which it confirmed the previously announced results and
_ which was signed by Balazs.
_
_ -- 5. On February 22, 2000, the Company announced over the PR
_ Newswire that Biomatrix product sales in 1999 were $72.0
_ million, up 90% from 1998 product sales of $37.8 million.
_ Defendants reported that product sales in the fourth quarter
_ of 1999 increased 53% to $19.3 million compared with product
_ sales of $12.6 million recorded during fourth quarter 1998 and
_ Balazs stated: "Biomatrix closed the century with its
_ strongest showing to date, proudly announcing its fourth
_ consecutive year of profitability."
On March 6, 2000, as alleged in the complaint, Balazs and Riggs announced that Biomatrix had agreed to merge into Genzyme Biosurgery, a new entity to be comprised of Biomatrix, Genzyme Tissue Repair and Genzyme Surgical Products. Genzyme agreed to pay cash at $37 per share for up to 28.38 % of the outstanding shares of Biomatrix common stock and to exchange Genzyme Biosurgery stock on a one-to-one basis for the remaining 71.62 % of the outstanding shares of Biomatrix stock. Under this agreement, as the owners of 6,751,506 shares between them, Balazs and his wife Denlinger stand to receive a minimum of $70 million in cash and 4.8 million shares of the new Company. As the owner of 1,746,000 Biomatrix shares, Riggs stands to receive $18 million in cash and 1.2 million shares of the new company. Balazs, Riggs and the Company`s other executive officers, who together own 37 % of Biomatrix`s outstanding shares, agreed to vote their shares in favor of the merger.
In announcing the merger, as alleged in the complaint, Riggs admitted that the Company was "off end user sales," and that the data shows that wholesalers are not purchasing as much in January but continued to conceal the fact that the Company was experiencing reduced cash flow due to Wyeth`s refusal to continue to build its inventory of Synvisc.
On April 25, 2000, as alleged in the complaint, the Company announced first-quarter revenues of $16.7 million and net income of $0.5 million or $0.02 per diluted share. The Company claimed that "Biomatrix ended the first quarter of 2000 with $33.3 million in cash and $78 million in shareholders` equity." By this time as awareness of the Company`s practice of building inventory had spread, the Company`s share price had dropped to $19 15/16, down 85% from a Class Period high of $37 on March 1, 2000.
On May 15, 2000, as alleged in the complaint, the Company filed its form 10-Q with the SEC for the first quarter ending March 31, 2000 in which it revealed that for the three months ended March 31, 2000, the Company had negative cash flow from operations of $1.3 million related to an increase in accounts receivable as a result of timing of shipments in the first quarter.
If you are a member of the proposed class, as defined above, and you wish to file a motion to serve as Lead Plaintiff in the Action, you must file such a motion by September 19, 2000 in the Office of the Clerk of the United States District Court for the District of New Jersey, Martin Luther King, Jr., Federal Building and U.S. Courthouse, 50 Walnut Street, Newark, New Jersey 07101.
The Private Securities Litigation Reform Act of 1995 (the "PSLRA") sets forth the following requirements, among others, for any person seeking to serve as a representative:

_ Each plaintiff seeking to serve as a representative party on
_ behalf of a class shall provide a sworn certification, which
_ shall be personally signed by such plaintiff and filed with
_ the complaint, that:
_
_ -- (1) states that the plaintiff has reviewed the complaint and
_ authorized its filing;
_
_ -- (2) states that the plaintiff did not purchase the security
_ that is the subject of the complaint at the direction of the
_ plaintiff`s counsel or in order to participate in any private
_ action arising under this chapter;
_
_ -- (3) states that the plaintiff is willing to serve as a
_ representative party on behalf of a class, including providing
_ testimony at deposition and trial, if necessary;
_
_ -- (4) sets forth all of the transactions of the plaintiff in the
_ security that is the subject of the complaint during the class
_ period specified in the complaint;
_
_ -- (5) identifies any other action under this chapter, filed
_ during the 3-year period preceding the date on which the
_ certification is signed by the plaintiff, in which the
_ plaintiff has sought to serve as a representative party on
_ behalf of a class; and
_
_ -- (6) states that the plaintiff will not accept any payment for
_ serving as a representative party on behalf of a class beyond
_ the plaintiff`s pro rata share of any recovery, except as
_ ordered or approved by the court in accordance with paragraph
_ (4). 15 U.S.C.ss.78 u-4(a)(2)(A)(i)-(iv).
In addition, the PSLRA provides that the Court shall appoint as Lead Plaintiff the member or members of the class that the Court determines to be most capable of adequately representing the interests of class members. In determining the "most adequate plaintiff," the PSLRA provides that the Court shall adopt a rebuttable presumption that the most adequate plaintiff is the person or group that has either filed a complaint or made a motion for appointment as Lead Plaintiff, has the largest financial interest in the relief sought by the class, and otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure. 15 U.S.C. ss. 78 u- 4(a)(3)(iii). At the Lead Plaintiff selection stage, this latter requirement involves a preliminary showing that the proposed Lead Plaintiff`s claims are typical of the claims of the class members, and that the Lead Plaintiff will be an adequate representative of the class. Any member of the alleged class may seek to be appointed as Lead Plaintiff, even if that person has not filed a complaint.
If you wish any further information concerning the Action, please contact the following attorneys: Steven G. Schulman or Samuel H. Rudman, One Pennsylvania Plaza, 49th fl. New York, NY, 10119-0165; Phone number: [phone]; Website: http://www.milberg.com
In addition, the complaint is on file in the Courthouse and may be reviewed in the office of the Clerk of the Court, Room 4015.

[gholzbauer]

BXM 22$ := Mkp 500 mln.$
GZTR 5$ := Mkp 150 mln.$
GZSP 10$ := Mkp 150 mln.$

BXM ist also das Schwergewicht dieser Fusion, die Kurse der drei Unternehmen sind bis zur Fusion durch die Umtauschverhältnisse aneinander gekoppelt. Es könnte sich lohnen, BXM (statt GZTR) zu jetzt 22$ zu kaufen, da bis zu ein Drittel der BXM-Aktien angeblich für 38$ bar bezahlt werden sollen. Ich kann momentan allerdings diese Textstelle nicht finden.

gholzbauer

[Deryabah]

...und was ist jetzt aus der Fusion geworden?

[Deryabah]

Hallo Freunde der Genzyme-Tissue-Repair-Aktie!

Wie würdet ihr die weitere Entwicklung von GEZT einschätzen?

...gibt es womöglich Hoffnung?

[Deryabah]

hey leute!
bin ich etwa der einzig überlebende?

[actnow3]

Hallo Freunde,

war im Urlaub und bin jetzt wieder da.

War wohl etwas lange. Aber gut. Dieser Thread wächst ja auch relativ langsam.

Eigentlich sollten doch nun nach der Fusion die Synergie-Effekte den Aktienkurs beflügeln oder.

Well, wenn Ihr neue Infos zu GZTR habt dann raus damit.

Stay Long.

[Hemden]

für Normalsterbliche:

http://www.marketone.de/research/allgemein.php3?ID=10396

[actnow3]

Hallo Leute,

hat diese Aktie überhaupt etwas mit der Börse zutun, oder wie soll ich das denn nun verstehen.

Ich meine, die pendelt ja nur hin und her. Irgendwie ist dort überhaupt kein Licht am Ende des Tunnels.

Gibts da garnichts in der Pipeline. Jetzt haben die schon kooperiert aber immer noch down. Sollte man jetzt vielleicht aussteigen um endlich zur ruhe kommen oder was meint Ihr.

Ich habe das gefühl, das wir ein gutes Jahr auf die alten Höchtsstände warten müssen. Wenn dem so ist, gibt es durch aus bessere Bio-Tech werte als GZTR.

Bitte antworten.

@actnow3